▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #209 by analyst upside · 2026-09-16
AEON
AEON Biopharma, Inc.
Healthcare · Market Cap $13M · P/E 0x
ANALYST PRICE TARGET
+474.2%
implied upside to consensus target
Current Price $0.27
Consensus Target $1.52
Bull Target $2.1
Bear Target $1.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
3
Hold
0
Sell
0
52-Week Low $0.18
52-Week High $1.45
YTD Return -76.0%
FUNDAMENTALS
Market Cap $13M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.22
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.18
52-Week High $1.45
Current Price $0.27
Bear Target $1.0
Bull Target $2.1
● Now $0.27 ● Target $1.52
TRADING DATA
Avg Volume 6.6M
YTD Return -76.0%
Analyst Count 4
Consensus Buy
Upside to Target +474.2%
Last Updated 2026-09-16

ANALYST SUMMARY

AEON Biopharma, Inc. (AEON) is currently trading at $0.27 with a Wall Street consensus price target of $1.52, implying potential upside of 474.2% over the next 12 months. 4 analysts currently cover AEON, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $2.1, while the most cautious has a target of $1.0.

AEON operates in the Healthcare sector with a market capitalisation of $13M. The stock is down 76.0% year-to-date and is currently trading near the lower end of its 52-week range of $0.18 – $1.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

AZTR +353.2%
Azitra, Inc.
$10M · P/E 8.6x · Underperform
SPRO +342.5%
Spero Therapeutics, Inc.
$66M · P/E 8.1x · Buy
GTBP +733.3%
GT Biopharma, Inc.
$16M · P/E 0.1x · Buy
PTN +389.0%
Palatin Technologies, Inc.
$19M · P/E 121.6x · Hold
FBIO +341.8%
Fortress Biotech, Inc.
$83M · P/E 0.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for AEON, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-14 31% win rate (48 calls)
Aegis Capital reit
Buy → Buy 2025-10-08 Building track record
HC Wainwright & Co. reit
Buy → Buy 2024-10-01 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2024-08-14 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-07-10 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →